Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
148 results about "Choroidal neovascularization" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Choroidal neovascularization (CNV) is the creation of new blood vessels in the choroid layer of the eye. Choroidal neovascularization is a common cause of neovascular degenerative maculopathy (i.e. 'wet' macular degeneration) commonly exacerbated by extreme myopia, malignant myopic degeneration, or age-related developments.
Transscleral delivery
Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.
Owner:SANTEN PHARMA CO LTD
Injectable Combination Therapy for Eye Disorders
InactiveUS20090220572A1Compounds screening/testingPowder deliveryLiquid mediumRetinal neovascularization
Owner:POTENTIA PHARMA INC
Apparatus and methods for prevention of age-related macular degeneration and other eye diseases
InactiveUS20030105456A1Minor side effectsIncrease flexibilityLaser surgerySurgical instruments for heatingRadio frequencyLaser beams
Surgical apparatus and surgical methods are proposed for the prevention of age-related macular degeneration (AMD) and choroidal neovascularization (CNV), and other eye diseases such as glaucoma by removal of the sclera tissue to reduce its rigidity and increase the flood flow and decrease pressure in the choriocapillaris. The disclosed preferred embodiments of the system consists of a tissue ablation means and a control means of ablation patterns and a fiber delivery unit. The basic laser beam includes UV lasers and infrared lasers having wavelength ranges of (0.15-0.36) microns and (0.5-3.2) microns and diode lasers of about 0.98, 1.5 and 1.9 microns. AMD and CNV are prevented, delayed or reversed by using an ablative laser to ablate the sclera tissue in a predetermined patterns outside the limbus to increase the elasticity of the sclera tissue surrounding the eye globe The surgery apparatus also includes non-laser device of radio frequency wave, electrode device, bipolar device and plasma assisted device
Owner:LIN J T
Compstatin and analogs thereof for eye disorders
ActiveUS20070238654A1Inhibit expressionImprove in vivo stabilityCompounds screening/testingOrganic active ingredientsDiseaseRetinal neovascularization
The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and / or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and / or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions.
Owner:APELLIS PHARMA
Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
InactiveUS20060067935A1Reduces VEGF expressionReduce expressionGenetic material ingredientsAntibody ingredientsIn vivoBiology
Activated C3 (C3a) and its receptor (C3aR) and activated C5 (C5a) and its receptor (C5aR) have been shown to induce vascular endothelial growth factor (VEGF) expression in vitro and in vivo. Compositions and methods for inhibiting C3a, C3aR, C5a and C5aR for the treatment and / or prevention of neovascular disease are provided. Also provided are Novel therapeutic targets and diagnostic markers for choroidal neovascularization.
Owner:KENTUCKY UNIVERISTY OF
Method of inhibiting choroidal neovascularization
ActiveUS20050187241A1Reduce lossesQuick identificationBiocideSenses disorderAngiogenesis growth factorNeovascularization
The present invention relates to compositions and methods for inhibiting unwanted angiogenesis, particularly those of ocular tissues. The treatment, inhibition, and / or prevention of choroidal neovasculature (CNV) is provided, along with an animal model for CNV and imaging techniques that permit the screening of potential agents as anti-angiogenesis and anti-CNV agents.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Therapeutic agents for diseases involving choroidal neovascularization
ActiveUS20100034811A1Advancement of CNV could be suppressedSenses disorderAntibody ingredientsDiseaseNeovascularization
The present inventors focused on the fact that inflammation at the subretinal macular area enhances choroidal neovascularization, and developed pharmaceutical agents that suppress initiation or advancement of neovascularization by angiogenic factors such as VEGF. More specifically, the present inventors revealed that administering anti-IL-6 receptor monoclonal antibodies to mice treated with laser photocoagulation inhibits the development of choroidal neovascularization.
Owner:CHUGAI PHARMA CO LTD +1
Methods and compositions for treating conditions of the eye
InactiveUS7125542B2Improve treatment efficacyReduced and delayed recurrenceUltrasonic/sonic/infrasonic diagnosticsBiocideAnti angiogenesisPhotosensitizer
Provided are methods and compositions for the photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of the PDT method can be enhanced by combining the PDT with an anti-angiogenesis factor, for example, angiostatin or endostatin, or with an apoptosis-modulating factor. Furthermore, the selectivity and sensitivity of the PDT may be further enhanced by coupling a targeting moiety to the photosensitizer so as to target the photosensitizer to choroidal neovasculature.
Owner:MASSACHUSETTS EYE & EAR INFARY
Raav vector compositions and methods for the treatment of choroidal neovascularization
InactiveUS20060193830A1Prevention of variousTreatment of variousBiocideSenses disorderPIGMENT EPITHELIUM-DERIVED FACTORDisease
Disclosed are methods for the use of therapeutic polypeptide-encoding polynucleotides in the creation of transformed host cells and transgenic animals is disclosed. In particular, the use of recombinant adeno-associated viral (rAAV) vector compositions comprising polynucleotide sequences that express one or more mammalian PEDF or anti-angiogenesis polypeptides is described. In particular, the invention provides gene therapy methods for the prevention, long-term treatment and / or amelioration of symptoms of a variety of conditions and disorders in a mammalian eye, including, for example blindness, loss of vision, retinal degeneration, macular degeneration, and related disorders resulting from retinal or choroidal neovascularization in affected individuals.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +1
Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
Activated C3 (C3a) and its receptor (C3aR) and activated C5 (C5a) and its receptor (C5aR) have been shown to induce vascular endothelial growth factor (VEGF) expression in vitro and in vivo. Compositions and methods for inhibiting C3a, C3aR, C5a and C5aR for the treatment and / or prevention of neovascular disease are provided. Also provided are Novel therapeutic targets and diagnostic markers for choroidal neovascularization.
Owner:KENTUCKY UNIVERISTY OF
Prevention and treatment of complement-associated eye conditions
The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
Owner:GENENTECH INC
Method and apparatus for treating ischemic diseases
ActiveUS20100168646A1Formation of free chlorine is avoidedInhibition formationSenses disorderElectrotherapyDiabetic retinopathyRetinal Vascular Disorder
The present invention relates to the treatment of ischemic diseases, and more particularly, to treatment of diabetic retinopathy and ischemia of the retinal and choroidal tissues. The treatment, which will work in vitrectomized eyes as well as non-vitrectomized eyes, is based on selective and fractional electrolysis of the vitreous humor to produce oxygen and optionally active chlorine while simultaneously controlling pH. Oxygen or active chlorine can suppress or reverse the onset of diabetic retinopathy, other retinovascular diseases, and choroidal neovascularization.
Owner:UNIV OF SOUTHERN CALIFORNIA +1
Viral complement control proteins for eye disorders
InactiveUS20060142191A1Inhibit expressionImprove in vivo stabilityBiocideSenses disorderDiseaseCOMPLEMENT REGULATORS
The present invention provides compositions and methods for treating and / or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.
Owner:POTENTIA PHARMA INC
RNAi inhibition of CTGF for treatment of ocular disorders
RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs of the present invention.
Owner:NOVARTIS AG
Methods for treating a disease involving choroidal neovascularization by administering an IL-6 receptor antibody
ActiveUS8771686B2Advancement of CNV could be suppressedSenses disorderImmunoglobulins against cell receptors/antigens/surface-determinantsDiseaseNeovascularization
Owner:CHUGAI PHARMA CO LTD +1
Compositions and methods for treating ocular diseases
InactiveUS20150050277A1Dipeptide ingredientsNitro compound active ingredientsUveitisMacula lutea degeneration
Disclosed herein are compositions and methods for treating ocular diseases, inter alia, diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. These diseases or conditions are characterized by changes in the ocular vasculature whether progressive or non-progressive, whether a result of an acute disease or condition, or a chronic disease or condition.
Owner:EYEPOINT PHARMA INC
Prevention and treatment of complement-associated eye conditions
The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
Owner:GENENTECH INC
Viral Complement Control Proteins for Eye Disorders
InactiveUS20080075755A1Improve in vivo stabilityLow failure rateBiocideSenses disorderComplement control proteinOcular inflammation
The present invention provides compositions and methods for treating and / or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.
Owner:POTENTIA PHARMA INC
SD-OCT retina image CNV segmentation method based on concavity and convexity
ActiveCN106600614AOvercome the difficulty of blurred or missing lesion boundariesOvercoming the Effects of SegmentationImage analysisEpitheliumReflectivity
The invention discloses a spectral-domain optical coherence tomography (SD-OCT) retina image choroidal neovascularization (CNV) segmentation method based on concavity and convexity, and belongs to the technical field of image processing. The method comprises the following steps: first, estimating the retina and choroid area of an input SD-OCT image, and positioning the internal limiting membrane (ILM) and the choroid-sclera junction (CSJ); then, estimating the retina pigment epithelium (RPE) layer according to the gradual change feature of the reflectivity of the retina image, and estimating the Bruch's membrane (BM) layer based on the concavity and convexity of the RPE layer; and finally, estimating a preliminary CNV region according to the thickness difference between the RPE layer and the BM layer, and correcting the upper border of CNV to get a final CNV segmentation result. The experimental results show that the algorithm proposed in the invention can be used to segment CNV robustly and precisely, and is of great significance to facilitating subsequent CNV quantitative analysis and improving the work efficiency of doctors.
Owner:NANJING UNIV OF SCI & TECH
Partitioning algorithm for choroidal neovascularization in OCT image
ActiveCN107369160AImprove Segmentation AccuracyImprove relevanceImage enhancementImage analysisNetwork modelMultiple-scale analysis
The invention discloses a partitioning algorithm for choroidal neovascularization in an OCT image. The algorithm includes steps of S01, designing a structure prior learning method for a training image and constructing a structure prior matrix used for distinguishing a choroidal neovascularization zone and a background zone; S02, converting the OCT original image to a saliency enhancing image used for enhancing the saliency of the choroidal neovascularization zone based on the structure prior matrix; S03, adopting multi-scale analysis on the saliency enhancing image and dividing the saliency enhancing image into m scales; S04, acquiring m trained convolutionneural network model based on each scale training; S05, processing a testing image by utilizing the step S01, S02, S03 and performing testing by utilizing the trained convolutionneural network model in the step S04, outputting m portioning results and fusing the m partitioning results into the final partitioning result. By adopting the algorithm provided by the invention, the precision of partitioning of the choroidal neovascularization in the OCT image can be improved distinctively.
Owner:SUZHOU BIGVISION MEDICAL TECH CO LTD
Oxygenated ophthalmic composition
The present invention relates to oxygenated ophthalmic topical compositions and methods of administering oxygenated ophthalmic topical compositions. The present invention also encompasses methods for making and administering the oxygenated ophthalmic topical compositions for use in treating or ameliorating pathologic conditions, complications, diseases and symptoms related to hypoxia of the anterior eye structure, including corneal neovascularization (CNV), edema, abrasions, infections, infiltrates, dry eye syndrome, contact lens intolerance; and redness, blurred vision, discomfort, foreign body sensation, photophobia, and irritation.
Owner:CHYNN EMIL W +1
Prophylactic or therapeutic agent for retinal disease and method for prophylaxis or therapy of retinal disease using jnk (c-jun amino-terminal kinase) - inhibitory peptide, and use of the peptide
Intravitreal administration of a JNK-inhibitory peptide less than 150 amino acids in length, containing at least one D-amino acid, and having (a) a JNK-inhibitory sequence of at least any of SEQ ID NO: 1 and SEQ ID NO: 2, and (b) a transport sequence of at least any of SEQ ID NO: 3 and SEQ ID NO: 4 suppressed spermidine-induced retinal pigment epithelial damage, tunicamycin-induced photoreceptor cell damage, and laser-induced choroidal neovascularization. Thus, the JNK-inhibitory peptide of the present invention is useful for prophylaxis or therapy of a retinal disease. By the use of this JNK-inhibitory peptide, a drug and a method are provided which are capable of preventing or treating a retinal disease even by topical administration to the eye, and use of the JKN-inhibitory peptide for manufacturing the drug is also provided.
Owner:SANTEN PHARMA CO LTD
RNAi inhibition of CTGF for treatment of ocular disorders
Owner:NOVARTIS AG
Compositions and methods for treatment of macular degeneration and related conditions
InactiveUS20090117171A1BiocideOrganic active ingredientsOcular neovascularizationOcular inflammation
The present invention provides methods and compositions for treating and / or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or ocular inflammation. The methods comprise administering a composition comprising a compound that is an antagonist of a G protein coupled receptor, e.g., the C5a receptor, to a subject in need of treatment or prevention of age-related macular degeneration or another condition involving macular degeneration or ocular neovascularization. The invention provides compositions comprising a compound that is an antagonist of a G protein coupled receptor linked either directly or indirectly to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization.
Owner:POTENTIA PHARMA INC
Formulations for ocular treatment
Diseases and conditions associated with tissues of the body, including tissues in the eye, can be effectively treated by administering therapeutic agents to those tissues. Described herein are self-emulsifying formulations and methods for delivering therapeutic agents to such tissues. A self-emulsifying formulation may be delivered to an aqueous medium of a subject, including but not limited to the vitreous. A method may, for instance, be used to administer rapamycin or related compounds to treat or prevent choroidal neovascularization associated with age-related macular degeneration, or to treat dry AMD. A self-emulsifying formulation may also be administered systernically, such as orally, to treat transplant rejection in a subject. A self-emulsifying formulation may comprise rapamycin, related compounds, or other therapeutic agents.
Owner:SANTEN PHARMA CO LTD
Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
InactiveUS20020128291A1Prevent proliferationPotent ability AP1-dependantBiocidePowder deliveryDiseaseLiposome
Proliferation of retinal pigment epithelium following surgery or trauma or resulting in ocular diseases associated with choroidal neovascularization, such as age related macular degeneration and histoplasmosis syndrome, is prevented by contacting retinal pigment epithelium cells with a therapeutic amount of a retinoic acid receptor (RAR agonist, preferably one with specific activity for retinoic acid receptors. Preferably the RAR agonist is also a potent antagonist of AP1-dependent gene expression. Alternatively, the proliferation of retinal pigment epithelium is ameliorated with a therapeutic amount of an AP-1 antagonist, alone or in combination with an RAR agonist. The drug can be administered by bolus injection into the vitreous cavity using a dosage from about 50 to 150 .mu.g. Or by slow release from liposomes or an oil tamponade injected into the vitreous cavity. Formulations for preventing proliferation of retinal pigment epithelium are also provided.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disorders
InactiveUS20080025973A1Attenuating Smad signalingReduce signalingBiocideSenses disorderDiabetic retinopathyDisease
Antagonists of S1P3 (Edg-3) receptors are provided for attenuation of Smad signaling in a method of down-regulation of receptor signaling and downstream decreased production of connective tissue growth factor in ocular disorders involving CTGF accumulation. Ocular disorders involving inappropriate CTGF accumulation include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and ocular wound healing, for example. Such disorders are treated by administering antagonists of the present invention.
Owner:ALCON RES LTD
Compositions and methods for treating ocular diseases
Disclosed are methods for treating diseases or conditions of the eye, especially retinopathies, ocular edema and ocular neovascularization. Non-limiting examples of these diseases or conditions include diabetic macular edema, age-related macular degeneration (wet or dry form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. These diseases or conditions are characterized by changes in the ocular vasculature whether progressive or non-progressive, whether a result of an acute disease or condition, or a chronic disease or condition.
Owner:AKEBIA THERAPEUTICS
Methods for the treatment and prevention of angiogenic diseases
InactiveUS20060270631A1Improve leakageLower Level RequirementsOrganic active ingredientsBiocideDiabetic retinopathyArthritis
The invention includes processes mainly for the treatment of angiogenic diseases, such as diabetic retinopathy, arthritis, cancer, psoriasis, Kaposi's sarcoma, hemangiomas, myocardial angiogenesis, atherosclerosis, and ocular angiogenic diseases such as choroidal neovascularization, retinopathy of prematurity (retrolental fibroplasias), macular degeneration, corneal graft rejection, rubeosis, neuroscular glacoma and Oster Webber syndrome. The processes involve treating a patient with a pharmaceutical composition containing an active ingredient that inhibits the activity of sphingosine kinase.
Owner:SMITH CHARLES D +2
Inhibition of choroidal neovascularization
InactiveUS20120301439A1Promotes cholesterol effluxReduce activationBiocideSenses disorderDiabetic retinopathyWhole body
Methods of treatment of diseases that include or are characterized by inappropriate or pathological neovascularization are disclosed. These diseases include diseases of the eye, such as diabetic retinopathy, retinopathy of prematurity, and choroidal neovascularization which can occur in age-related macular degeneration (AMD). Disclosed methods include administering agents that cause directly or indirectly upregulation of the ABCA1 transporter protein in macrophages. These agents include, without limitation, LXR agonists. In some embodiments, inhibitors of CETP expression or activity can also be effective. Administration routes can include, without limitation, intraocular, periocular, or systemic administration.
Owner:WASHINGTON UNIV IN SAINT LOUIS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com